FindTrial
Sign In

D-Galactose

DIETARY_SUPPLEMENT3 trials

Sponsors

Children's National Research Institute, Tulane University, Hospital Ruber Internacional

Conditions

Congenital Disorders of GlycosylationFocal Segmental GlomerulosclerosisRefractory EpilepsySLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of GlycosylationSteroid Resistant Nephrotic Syndrome

Unknown Phase

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
CompletedNCT01113385
Children's National Research InstituteFocal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Start: 2009-10-31End: 2013-03-31Updated: 2014-09-15
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation
CompletedNCT02955264
Tulane UniversityCongenital Disorders of Glycosylation
Start: 2014-07-31End: 2018-01-31Updated: 2021-01-08
Galactose Supplementation for the Treatment of MOGHE
NCT04833322
Hospital Ruber InternacionalRefractory Epilepsy, SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
Start: 2021-01-15End: 2021-10-01Target: 8Updated: 2021-04-06

Related Papers

D-galactose Supplementation for the Treatment of Mild Malformation of Cortical Development with Oligodendroglial Hyperplasia in Epilepsy (MOGHE): A Pilot Trial of Precision Medicine After Epilepsy Surgery.
2023-06-0613 citations
D-galactose supplementation in individuals with PMM2-CDG: results of a multicenter, open label, prospective pilot clinical trial.
2021-03-2013 citations